The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta‐analysis
Abstract
We performed a Bayesian network meta‐analysis combining direct and indirect treatment comparisons to assess the comparative effectiveness of pharmacological agents for the treatment of nonalcoholic steatohepatitis (NASH). Through systematic literature review, we identified nine randomized, controlled trials (RCTs) including 964 patients with biopsy‐proven NASH, comparing vitamin E, thiazolidinediones (TZDs), pentoxifylline, or obeticholic acid to one another or placebo. The primary outcome was improvement in fibrosis stage; secondary outcomes were improvement in ballooning degeneration, lobular inflammation, and steatosis. We reported relative risks (RRs) and 95% confidence intervals (CIs) from direct meta‐analysis and 95% credible intervals (CrIs) from Bayesian network meta‐analysis, and used Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria to appraise quality of evidence. Moderate‐quality evidence supports the use of pentoxifylline (RR, 0.26; 95% CrI: 0.05‐1.00) and obeticholic acid (RR, 0.81; 95% CI: 0.70‐0.95) over placebo in improving fibrosis. High‐quality evidence supports the effect of vitamin E, TZDs, and obeticholic acid over placebo in improving ballooning degeneration. All four interventions seemed to have at least moderate‐quality evidence over placebo to improve steatosis. Moderate‐quality evidence supports that TZDs, pentoxifylline, and obeticholic acid decrease lobular inflammation. All the head‐to‐head comparisons were supported by very‐low‐quality evidence except for superiority of TZDs over vitamin E on improving steatosis and lobular inflammation, which had moderate‐quality evidence. Conclusions: Based on direct and network meta‐analysis, pentoxifylline and obeticholic acid improve fibrosis, and vitamin E, TZDs, and obeticholic acid improve ballooning degeneration in patients with NASH. Future comparative trials of combination therapies targeting distinct histological features are warranted. (H epatology 2015;62:1417–1432)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Puhan, M. A., Schunemann, H. J., Murad, M. H., Li, T., Brignardello-Petersen, R., Singh, J. A., Kessels, A. G., Guyatt, G. H., & for the GRADE Working Group (2014) · BMJ · doi:10.1136/bmj.g5630 · Cited by 1,812 · cited 3×
“We followed the GRADE approach to rate the quality of evidence of estimates derived from network meta-analysis.(17,27) In this approach, direct evidence from RCTs starts at high quality and can be rated down, based on risk of bias, indirectness, imprecision, inconsistency (or heterogeneity), and/or publication bias, t…”
BackgroundMethodSelf-citationSingh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Self-citationDias, S., Sutton, A. J., Ades, A. E., & Welton, N. J. (2013) · Medical Decision Making · doi:10.1177/0272989x12458724 · Cited by 1,207
Conceptual and technical challenges in network meta-analysis
Cipriani, A., Higgins, J. P. T., Geddes, J. R., & Salanti, G. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-2-201307160-00008 · Cited by 1,072
Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625
Boettcher, E., Csako, G., Pucino, F., Wesley, R., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04912.x · Cited by 318
Self-citationHutton, B., Salanti, G., Chaimani, A., Caldwell, D. M., Schmid, C., Thorlund, K., Mills, E., Catalá-López, F., Turner, L., Altman, D. G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092508 · Cited by 105
Cited by
Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Non-alcoholic fatty liver disease and dyslipidemia: An update
Katsiki, N., Mikhailidis, D. P., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.003 · Cited by 564
Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis
Koo, B. K., Kim, D., Joo, S. K., Kim, J. H., Chang, M. S., Kim, B. G., Lee, K. L., & Kim, W. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.019 · Cited by 440
Loomba, R., Lim, J. K., Patton, H., & El-Serag, H. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.053 · Cited by 357
Self-citationBril, F., Biernacki, D. M., Kalavalapalli, S., Lomonaco, R., Subbarayan, S. K., Lai, J., Tio, F., Suman, A., Orsak, B. K., Hecht, J., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0167 · Cited by 312
Metadata
- Authors
- Singh, S., Khera, R., Allen, A. M., Murad, M. H., & Loomba, R.
- Venue
- Hepatology
- Published
- 2015-10-01
- Volume
- 62
- Issue
- 5
- Pages
- 1417-1432
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W1866142084
- Cited by
- 163
- References
- 10
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta‐analysis. https://app.cochat.ai/papers/10.1002/hep.27999
- The paper
- Singh, S., Khera, R., Allen, A. M., Murad, M. H., & Loomba, R. (2015). Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta‐analysis. Hepatology. https://doi.org/10.1002/hep.27999
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.